Skip to content
★ Sign in to follow
이노

이노진 Stock: price and insider trades · South Korea

KR·Mcap ₩14.8BHealth Care

2 insiders bought €559k of shares over the last 90 days, the latest by 메타몰퍼시스, filed 24 Aug 2026.

이노진: what insiders have been doing

이노진 is a Health Care company. Its directors and officers file their transactions with DART (FSS). In the past year (2 November 2025 to 2 November 2026), 4 filings came from 3 insiders.

Purchases and sales both appear in the filings: 3 purchases (2 insiders) and 1 sale (1 insider). The amount is not disclosed for 4 filings. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Those buying include 1 chief executive.

The clock since the last published purchase (24 August 2026) now reads 78 days.

Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 4 filings, this issuer sits below that mark. Looking back to 2021, when coverage begins, insiders filed 11 purchases and 4 sales.

In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. Source: insider filings from DART (FSS). Past trades are no guide to future returns.

Insider Decl.
16
Thresholds
n/a
Buy Volume
€6M
11 ops. · all time
Sell Volume
€3M
4 ops. · all time

Who traded when

BuySale
메타몰퍼시스2 buys
Antonius Rachmat Soelistyo1 sale
정기철1 buy
Fundamental score
Ranked 11,532 of 26,911 companies
55.3
score / 100
Value
37
Quality
74
FCF yld2.9%
Earn yld2.0%
EV/EBITDA28.3x
ROE·
Gross mgn76%
Net mgn3.5%
Debt/EBITDA0.2x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩1,401
Analyst consensus
·
Income statement
Revenue₩8.2B
Gross profit₩6.2B76% margin
EBITDA₩503.4M6% margin
Net income₩287.9M3.5% margin
Balance sheet & cash
Market cap₩14.8B
Total debt₩99.5M
Free Cash Flow₩411.4M
Last declaration on 24 August 2026
Declarations22 total
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • ▲
    10%이상주주Executives(filed)
    €456kest.0DART
    570,000 sharesShareKRXDART:20260824000334
    Canonical exit: 22 Nov 2026 (T+90)
  • Other
    Other(filed)
    0DART
  • ▲
    공동대표이사Executives(filed)
    €103kest.0DART
    120,000 sharesShareKRXDART:20260813001039
    Canonical exit: 11 Nov 2026 (T+90)
  • Other
    Other(filed)
    0DART
  • ▲
    10%이상주주Executives(filed)
    €1.7Mest.0DART
    2,280,000 sharesShareKRXDART:20260803000297
    Canonical exit: 1 Nov 2026 (T+90)
  • Other
    Other(filed)
    0DART
  • ▼
    Executives
    €174kest.0DART
    190,892 sharesKRXDART:20260408002854
  • ▼
    Executives
    €700kest.0DART
    572,000 sharesKRXDART:20241025000171
  • ▲
    대량보유자Executives
    €1.3Mest.0DART
    719,500 sharesKRXDART:20240215001137
    Canonical exit: 21 May 2023 (T+90)
  • ▲
    대량보유자Executives
    €1.4Mest.0DART
    778,780 sharesKRXDART:20240215001051
    Canonical exit: 21 May 2023 (T+90)
  • ▲
    Executives
    €1.5Mest.0DART
    400,000 sharesShareKRXDART:20230222003297
    Canonical exit: 13 Jul 2022 (T+90)
  • ▲
    Executives(filed)
    0DART
    778,780 sharesKRXDART:20230223001767
    Canonical exit: 24 May 2023 (T+90)
  • ▲
    Executives
    0DART
    3,320,000 sharesShareKRXDART:20230222003290
    Canonical exit: 13 Jul 2022 (T+90)
  • ▲
    Executives(filed)
    0DART
    719,500 sharesKRXDART:20230223000098
    Canonical exit: 24 May 2023 (T+90)
  • ▲
    Executives(filed)
    0DART
    719,500 sharesKRXDART:20230222003247
    Canonical exit: 24 May 2023 (T+90)
  • ▲
    Executives(filed)
    0DART
    3,960,000 sharesKRXDART:20230222001660
    Canonical exit: 23 May 2023 (T+90)
  • ▼
    Executives(filed)
    €869kest.0DART
    572,000 sharesKRXDART:20210901000174
  • ●
    Executives
    Executives(filed)
    0DART
  • ▼
    Executives(filed)
    €864kest.0DART
    572,000 sharesKRXDART:20210827000141

22 of 22 declarations

About 이노진

이노진 is a healthcare and pharmaceutical company listed on the XKRX market. It focuses on developing innovative solutions to enhance patient health.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations